Nasdaq gnlx.

WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...

Nasdaq gnlx. Things To Know About Nasdaq gnlx.

Oct 5, 2023 · Find the latest historical data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. Genelux Corporation (NASDAQ:GNLX) gained 10.5% to $5.02. Latham Group, Inc. (NASDAQ:SWIM) gained 10.2% to $3.7050 following Q4 results. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) rose 9.6% to $7.75 ...View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news.GNLX - Genelux Corp - Stock screener for investors and traders, financial ... Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

GNLX stock had a volatile day of trading on September 19, 2023, with significant fluctuations in its price. The stock opened at $21.93 and ranged from $21.93 to $25.85 throughout the day. The trading volume for GNLX on September 19 was 14,269 shares, considerably lower than the average volume of 124,690 shares over the past …add_box. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...WebWESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology …

GNLX stock had a volatile day of trading on September 19, 2023, with significant fluctuations in its price. The stock opened at $21.93 and ranged from $21.93 to $25.85 throughout the day. The trading volume for GNLX on September 19 was 14,269 shares, considerably lower than the average volume of 124,690 shares over the past …

WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...Nov 23, 2023 · Nelly Dodson. November 23, 2023. Business. Genelux Corp (NASDAQ:GNLX)’s traded shares stood at 76372.0 during the last session. At the close of trading, the stock’s price was $11.19, to imply an increase of 7.80% or $0.81 in intraday trading. The GNLX share’s 52-week high remains $40.98, putting it -266.22% down since that peak but still ... Stock analysis for Genelux Corp (GNLX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.The latest price target for Genelux ( NASDAQ: GNLX) was reported by Maxim Group on Tuesday, September 12, 2023. The analyst firm set a price target for 40.00 expecting GNLX to rise to within 12 ...

WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, …

In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.

Based on analysts offering 12 month price targets for GNLX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your ...In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.WebWESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...WebOn September 18, 2023, John Thomas, a director at Genelux Corp ( NASDAQ:GNLX ), sold 6,667 shares of the company. This move comes amidst a year where the insider has sold a total of 6,667 shares ...Genelux press release (NASDAQ:GNLX): Q2 GAAP EPS of -$0.23.; At June 30, 2023, the company had cash on hand in the amount of $27.1 million. Net loss was $5.8 million for the second quarter of 2023 ...Nov 14, 2023 · WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...

Find the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Jul 11, 2023 · CIPhotos. Genelux ( NASDAQ: GNLX) is an immuno-oncology frontrunner that presents a promising investment opportunity in the fight against cancer. With its cutting-edge technology platform, strong ... WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.Genelux is a publicly-traded biopharmaceutical company (Nasdaq: GNLX). It currently is conducting a Phase 3 registrational trial in resistant/refractory ...

Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...

Nasdaq. 14,305.03 +78.81 (+0.55%) ... the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final ...IPO preview: IPOs that could start trading next week include biopharma Genelux Corporation (NASDAQ:GNLX) and tech firm Beamr Imaging Ltd . The quiet periods on Corebridge Financial ...Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...WebGenelux Corporation Common Stock (GNLX) Nasdaq Listed; Nasdaq 100; Data is currently not available. Bid: Ask: Volume: 0. ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Genelux (NASDAQ:GNLX) director Szalay Aladar continued to dispose of his stake in the biopharmaceutical company. Aladar sold 42,263 shares of indirect ownership, held by The Szalay 2010 Retained ...GNLX | Complete Genelux Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.WebWESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the ...

The average price predicted for Genelux Corp (GNLX) by analysts is $36.00, which is $22.03 above the current market price. The public float for GNLX is 18.34M, and at present, short sellers hold a 4.76% of that float. On November 07, 2023, the average trading volume of GNLX was 223.78K shares. Top 5 AI Stocks to Buy for 2023.

Genelux (NASDAQ:GNLX) opened up its shares for public trading for the first time since it filed for IPO in June 2022. The company agreed to initially offer 2.50 million shares to the public at $6.00 per share. ... For its IPO, GNLX agreed to offer 2.50 million shares at a price of $6.00 per share, with an insider lock-up period of 180 days ...

WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ... WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...Genelux Corporation (NASDAQ:GNLX) gained 10.5% to $5.02. Latham Group, Inc. (NASDAQ:SWIM) gained 10.2% to $3.7050 following Q4 results. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) rose 9.6% to $7.75 ...WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WebIn the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.26. 10. 2023 ... Genelux raised $15.9 million in January pricing shares at $6 each. The stock (NASDAQ:GNLX) closed at $18.69 on Oct. 25, a 211.5% increase. Also ...Given GNLX’s positive Phase 2 trial results to-date, my outlook on IPO is a Buy for patient, risk-tolerant life science investors with a long-term hold time frame. ... (NASDAQ:GNLX) was founded ...WebWESTLAKE VILLAGE, Calif. - Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000 Index and small-cap Russell 2000 at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on …WebGenelux Corporation (NASDAQ:GNLX) gained 12.9% to $30.82. Franchise Group, Inc. (NASDAQ:FRG) jumped 11.8% to $25.44. Franchise Group revealed the receipt of an unsolicited non-binding proposal to ...

Genelux Corp · Last Price. 28.77. As of Sep 20, 2023 · Sector. Healthcare · Industry. Biotechnology · Investment Style. — · Day Range. 26.07 – 29.36 · Year ...Genelux Corporation (NASDAQ:GNLX) 10% owner Aladar Szalay disclosed after the bell on Oct. 26 the sale of an aggregate of 5,704 shares for about $110,637. Aladar Szalay had disclosed another sale ...What happenedShares of Genelux Corporation (NASDAQ: GNLX) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company ...NVIDIA Corporation Common Stock. $435.70 -0.93 -0.21%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...Instagram:https://instagram. luv pricehigh value stocksvanguard value of an advisorbest self managed ira Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of November 1 ...Web tight spread forex brokersilver projected price GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...On June 16, 2023, the NASDAQ:GNLX stock opened at $34.06, representing a significant increase from its one-year low of $5.35 and a modest uptick from its impressive one-year high of $39.27. The stock’s 50-day simple moving average is currently resting at $26.83, indicating a positive trend that is grabbing the attention of expert market analysts. credit union vs bank home loan Dec 1, 2023 · A high-level overview of Genelux Corporation (GNLX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 ...WebGenelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million ...